NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.15. The biopharmaceutical company earned $39.34 million during the quarter, compared to analysts' expectations of $35.89 million. Acceleron Pharma had a negative return on equity of 30.79% and a negative net margin of 353.57%. The firm's revenue for the quarter was up 929.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.75) earnings per share. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Acceleron Pharma.

14 analysts have issued 12 month price objectives for Acceleron Pharma's shares. Their forecasts range from $55.00 to $138.00. On average, they anticipate Acceleron Pharma's share price to reach $99.08 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

Headlines about XLRN stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Acceleron Pharma earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Acceleron Pharma.

Some companies that are related to Acceleron Pharma include NOVOZYMES A/S/S (NVZMY), Moderna (MRNA), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BioNTech (BNTX), BIO-TECHNE (TECH), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (GILD), Incyte (INCY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Intel (INTC), LogicBio Therapeutics (LOGC) and Bausch Health Companies (BHC).

Acceleron Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Farallon Capital Management LLC (3.77%), State Street Corp (2.75%), Westfield Capital Management Co. LP (2.17%), Janus Henderson Group PLC (2.14%) and Eagle Asset Management Inc. (1.72%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Investments Inc., Janus Henderson Group PLC, Credit Suisse AG, AXA, Westfield Capital Management Co. LP, Candriam Luxembourg S.C.A. and Alliancebernstein L.P.. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Great Lakes Advisors LLC, Aviva PLC, Artisan Partners Limited Partnership, State Street Corp, Cubist Systematic Strategies LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $85.93.

Acceleron Pharma has a market capitalization of $4.56 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]